Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer (English)
- New search for: Vrdoljak, E.
- New search for: Marschner, N.
- New search for: Zielinski, C.
- New search for: Gligorov, J.
- New search for: Cortes, J.
- New search for: Puglisi, F.
- New search for: Aapro, M.
- New search for: Fallowfield, L.
- New search for: Fontana, A.
- New search for: Inbar, M.
- New search for: Vrdoljak, E.
- New search for: Marschner, N.
- New search for: Zielinski, C.
- New search for: Gligorov, J.
- New search for: Cortes, J.
- New search for: Puglisi, F.
- New search for: Aapro, M.
- New search for: Fallowfield, L.
- New search for: Fontana, A.
- New search for: Inbar, M.
In:
ANNALS OF ONCOLOGY
;
27
, 11
;
2046-2052
;
2016
-
ISSN:
- Article (Journal) / Print
-
Title:Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
-
Contributors:Vrdoljak, E. ( author ) / Marschner, N. ( author ) / Zielinski, C. ( author ) / Gligorov, J. ( author ) / Cortes, J. ( author ) / Puglisi, F. ( author ) / Aapro, M. ( author ) / Fallowfield, L. ( author ) / Fontana, A. ( author ) / Inbar, M. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 27, 11 ; 2046-2052
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2016-01-01
-
Size:7 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 27, Issue 11
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1977
-
Ovarian cancer mortality trends: which factors are involved?Weiderpass, E. / Botteri, E. et al. | 2016
- 1978
-
The role of opioids in cancer progression: emerging experimental and clinical implicationsSjøgren, P. / Kaasa, S. et al. | 2016
- 1981
-
Statistical controversies in clinical research: should schedules of tumor size assessments be changed?Filleron, T. / Kouokam, W. / Gilhodes, J. / Duhamel, A. / Penel, N. / Joly, F. / Tresch-Bruneel, E. / Kramar, A. / Houédé, N. et al. | 2016
- 1988
-
The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population?Papatla, K. / Huang, M. / Slomovitz, B. et al. | 2016
- 1994
-
Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issuesBentivegna, E. / Gouy, S. / Maulard, A. / Pautier, P. / Leary, A. / Colombo, N. / Morice, P. et al. | 2016
- 2004
-
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscapeOlaussen, K. A. / Postel-Vinay, S. et al. | 2016
- 2017
-
Global trends and predictions in ovarian cancer mortalityMalvezzi, M. / Carioli, G. / Rodriguez, T. / Negri, E. / La Vecchia, C. et al. | 2016
- 2025
-
No ‘cure’ within 12 years of diagnosis among breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989–2011Woods, L. M. / Morris, M. / Rachet, B. et al. | 2016
- 2032
-
Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancerJanku, F. / Johnson, L. K. / Karp, D. D. / Atkins, J. T. / Singleton, P. A. / Moss, J. et al. | 2016
- 2039
-
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)Aapro, M. / Ludwig, H. / Bokemeyer, C. / Gascón, P. / Boccadoro, M. / Denhaerynck, K. / Krendyukov, A. / Gorray, M. / MacDonald, K. / Abraham, I. et al. | 2016
- 2046
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancerVrdoljak, E. / Marschner, N. / Zielinski, C. / Gligorov, J. / Cortes, J. / Puglisi, F. / Aapro, M. / Fallowfield, L. / Fontana, A. / Inbar, M. et al. | 2016
- 2053
-
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN studyFurlanetto, J. / Eiermann, W. / Marmé, F. / Reimer, T. / Reinisch, M. / Schmatloch, S. / Stickeler, E. / Thomssen, C. / Untch, M. / Denkert, C. et al. | 2016
- 2059
-
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY studyVuylsteke, P. / Huizing, M. / Petrakova, K. / Roylance, R. / Laing, R. / Chan, S. / Abell, F. / Gendreau, S. / Rooney, I. / Apt, D. et al. | 2016
- 2067
-
Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patientsCho, Y. / Kim, K. H. / Yoon, H. I. / Kim, G. E. / Kim, Y. B. et al. | 2016
- 2074
-
Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial†Lonardi, S. / Sobrero, A. / Rosati, G. / Di Bartolomeo, M. / Ronzoni, M. / Aprile, G. / Scartozzi, M. / Banzi, M. / Zampino, M. G. / Pasini, F. et al. | 2016
- 2082
-
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression†Obermannová, R. / Van Cutsem, E. / Yoshino, T. / Bodoky, G. / Prausová, J. / Garcia-Carbonero, R. / Ciuleanu, T. / Garcia Alfonso, P. / Portnoy, D. / Cohn, A. et al. | 2016
- 2090
-
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trialIkeda, M. / Shimizu, S. / Sato, T. / Morimoto, M. / Kojima, Y. / Inaba, Y. / Hagihara, A. / Kudo, M. / Nakamori, S. / Kaneko, S. et al. | 2016
- 2097
-
Toward the molecular dissection of peritoneal pseudomyxomaPietrantonio, F. / Perrone, F. / Mennitto, A. / Gleeson, E. M. / Milione, M. / Tamborini, E. / Busico, A. / Settanni, G. / Berenato, R. / Caporale, M. et al. | 2016
- 2103
-
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsYang, J. C. / Sequist, L. V. / Zhou, C. / Schuler, M. / Geater, S. L. / Mok, T. / Hu, C. P. / Yamamoto, N. / Feng, J. / O'Byrne, K. et al. | 2016
- 2111
-
Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinibMansfield, A. S. / Murphy, S. J. / Harris, F. R. / Robinson, S. I. / Marks, R. S. / Johnson, S. H. / Smadbeck, J. B. / Halling, G. C. / Yi, E. S. / Wigle, D. et al. | 2016
- 2117
-
Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancerKinoshita, T. / Muramatsu, R. / Fujita, T. / Nagumo, H. / Sakurai, T. / Noji, S. / Takahata, E. / Yaguchi, T. / Tsukamoto, N. / Kudo-Saito, C. et al. | 2016
- 2124
-
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancerLiu, J. F. / Moore, K. N. / Birrer, M. J. / Berlin, S. / Matulonis, U. A. / Infante, J. R. / Wolpin, B. / Poon, K. A. / Firestein, R. / Xu, J. et al. | 2016
- 2131
-
Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies?Roviello, G. / Generali, D. et al. | 2016
- 2133
-
Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.Kim, S. J. / Kim, W. S. et al. | 2016
- 2134
-
Utilisation of the ESMO-MCBS in practice of HTAWild, C. / Grössmann, N. / Bonanno, P. V. / Bucsics, A. / Furst, J. / Garuoliene, K. / Godman, B. / Gulbinovič, J. / Jones, J. / Pomorski, M. K. et al. | 2016
- 2136
-
Reply to the letter to the editor ‘Utilisation of the ESMO-MCBS in practice of HTA’ by Wild et al.Cherny, N. I. / Sullivan, R. / Dafni, U. / Bogaerts, J. / Kerst, J. M. / Zielinski, C. / Piccart, M. J. / de Vries, E. G. et al. | 2016
- 2137
-
Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trialCeccarelli, G. / Schietroma, I. / Corano Scheri, G. / d'Ettorre, G. / Vullo, V. et al. | 2016
- 2138
-
Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysisMyung, S. K. et al. | 2016
- 2138
-
Reply to the letter to the editor ‘Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysis, by S.-K. Myung’Bagnardi, V. / Botteri, E. / La Vecchia, C. et al. | 2016
- 2138
-
reply to the letter to the editor ‘Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial’ by Ceccarelli et al.Lacouture, M. E. et al. | 2016